P

Pfizer

Makes cancer drugs, vaccines and other medicines

Program Lead - Data Integrity & Audit Readiness

Full-TimePosted on 10/27/2026Deadline 11/11/26
$99.2k - $165.4k/yr
Mid
Bachelor's, Master's, PhD, Associate's
McPherson, KS, USA
HybridHybrid work assignment; onsite or flex schedule aligned with site/business requirements. Occasional travel may be required (0–10%).
Biology & BiotechRegulatory & Quality (Life Sciences)
No H1B Sponsorship

About the job

Requirements
  • A bachelor's degree with at least 4 years of experience, a master's degree with at least 2 years of experience, a PhD with 0+ years of experience, an associate's degree with 8 years of experience, or a high school diploma or equivalent with 10 years of relevant experience is required.
  • Strong knowledge of current Good Manufacturing Practice (cGMP) regulations and quality systems.
  • Experience supporting regulatory inspections and audit response activities.
  • Experience managing corrective and preventive actions (CAPAs), remediation programs, and compliance initiatives.
  • Demonstrated ability to lead complex cross-functional projects without direct authority.
  • Experience with electronic quality and business systems such as electronic quality management systems (eQMS), QTS, Sherlock, PDOC’s, laboratory information management systems (LIMS), SAP, Microsoft Word, and Microsoft Excel.
  • Demonstrated analytical skills and meticulous attention to detail.
  • Proficiency in taking decisive action based on quality and compliance metrics and trends.
  • Ability to manage multiple complex projects with business acumen.
  • Strong written and verbal communication, facilitation, and stakeholder management skills.
  • Ability to perform mathematical calculations and complex data analysis, and to work periodically on the manufacturing floor with heightened safety awareness; aseptic gowning may be required in applicable manufacturing areas.
  • Candidates must be authorized to be employed in the United States by any employer and must have permanent work authorization in the United States.
Responsibilities
  • Co-lead the site Data Integrity governance program and support implementation of global data integrity requirements.
  • Monitor and assess data integrity risks across systems, processes, and records.
  • Facilitate Data Integrity assessments, gap analyses, and remediation activities.
  • Partner with functional areas to ensure adherence to ALCOA+ principles and regulatory expectations.
  • Analyze data integrity trends and metrics to identify systemic risks and improvement opportunities.
  • Support development and execution of data integrity training, awareness programs, and communications.
  • Coordinate commitments resulting from regulatory inspections, customer audits, corporate audits, and internal assessments.
  • Establish and maintain governance processes for tracking commitments through completion and effectiveness verification.
  • Partner with commitment owners to develop action plans, milestones, and deliverables.
  • Monitor progress against commitments and escalate risks, delays, or resource constraints.
  • Prepare and present commitment status updates to site leadership and global stakeholders.
  • Ensure commitment documentation is inspection-ready and supports regulatory expectations.
  • Support site inspection readiness programs and regulatory preparedness activities.
  • Participate in inspection planning, response development, and post-inspection remediation efforts.
  • Review audit observations and commitments for alignment with quality system requirements and regulatory expectations.
  • Support development of responses to regulatory observations and compliance-related inquiries.
  • Maintain visibility of emerging compliance risks and recommend mitigation strategies.
  • Support continuous improvement initiatives related to compliance, quality systems, and data governance.
  • Drive or contribute to complex projects and team milestones and deliverables, exercising independent judgment under limited supervision.
  • Promote consistent application of root-cause analysis, human-error reduction tools, and investigation process improvements to meet changing business needs.
  • Exercise independent judgment using knowledge and experience with minimal assistance from management.
  • Provide peer leadership to mentor and develop colleagues.
  • Maintain and develop department standard operating procedures, monitoring alignment with regulations and Pfizer Quality Standards.
  • Support audit teams, manage vendor audit status, and communicate inspection trends to stakeholders while addressing identified gaps.
  • Work occasional evenings, weekends, or holidays as needed to support operations, investigations, or commitments; occasional travel of 0–10% may be required.
  • Perform work on the manufacturing floor as needed and follow applicable safe work practices and aseptic gowning requirements.
Desired Qualifications
  • Exceptional organizational and project management skills.
  • Experience in quality control and/or quality assurance within the pharmaceutical industry.
  • Experience in aseptic processes and operational knowledge.
  • Experience with data integrity governance programs.
  • Experience with inspections by the Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and other global regulatory agencies.
  • Knowledge of Quality Risk Management principles and methodologies.
  • Certification in Quality, Compliance, Project Management, or Lean Six Sigma.
  • Ability to adapt to changing priorities and manage multiple tasks simultaneously.
  • Experience using common artificial intelligence tools, including generative technologies such as ChatGPT or Microsoft Copilot, to support problem solving and enhance productivity; curiosity about improving outcomes with these tools and understanding of responsible artificial intelligence practices, including risk management and ethical use.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

-3%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 27th, 2026
AT&T, Pfizer and Zoetis offer yields up to 5.8% with shares under $100

Rising interest rates and bond yields have made dividend stocks less appealing, pushing many lower and their yields higher. Three that trade below $100 are AT&T, Pfizer, and Zoetis, according to The Motley Fool. AT&T trades around $21, down about 16% this year, with a price-to-earnings (P/E) multiple of 11 against 23 for the S&P 500. It yields 5.3% after revenue grew more than 5% in the September quarter. Pfizer trades near $30 and yields 5.8%. Its forward P/E is 10, though its shares are down more than 30% over five years. Zoetis, down 37% this year, trades below $80 with a P/E of 13 and a yield of about 2.6%. Its payout ratio is around 34% of earnings, and it has 12 potential blockbusters in its pipeline.

Yahoo Finance
Oct 22nd, 2026
Pfizer's 5.7% yield signals risk: dividends took 108% of free cash flow vs Merck's 66%

Merck's dividend looks safer than Pfizer's, despite Pfizer's higher yield, according to a 24/7 Wall St. comparison. Pfizer yields about 5.7% against Merck's 2.2%. In 2025, Pfizer's dividends used 108% of free cash flow, while Merck's used 66%. In the first half of 2026, Merck's free cash flow covered 174% of its payout; Pfizer's covered about 51%. Merck has raised its quarterly dividend 39% since 2020, to $0.85. Pfizer's rose 13% and has been flat at $0.43 since January 2025. Pfizer is cheaper, at about 10 times 2026 earnings against Merck's 17. Pfizer targets a return to growth from 2029, while Merck's newer drugs are already selling.

Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.